Prognostic significance of SUV on PET/CT in patients with esophageal cancer: a systematic review and meta-analysis

Eur J Gastroenterol Hepatol. 2009 Sep;21(9):1008-15. doi: 10.1097/MEG.0b013e328323d6fa.

Abstract

Background and purpose: Esophageal cancer is the third most common gastrointestinal malignancy with a poor long-term survival and high mortality. Surgical resection provides the only chance of cure. The tumor-node metastasis stage classification system is a strong prognostic parameter predicting the prognosis. We performed the present meta-analysis to comprehensively review the evidence for use of standardized uptake value (SUV) measured on tumor to predict prognosis of esophageal cancer.

Methods: We searched for articles published in English or Chinese; limited to esophageal cancer; F-fluoro-2-deoxy-glucose (F-FDG) uptake on positron emission tomography (PET) performed on a dedicated device; dealt with the impact of SUV on survival. We extracted an estimate of the log hazard ratios (HR) and their variances and performed meta-analysis.

Results: Without the study dealt by the pretreatment SUV measured on metastasis sites, there were seven studies dealt by the prognostic value of SUV measured on FDG-PET for overall survival. The combined HR was 1.86, meaning that high SUV indicated worse survival prognosis; and there were three studies dealt with the prognostic value of SUV measured on FDG-PET for disease-free survival. The combined HR was 2.52, indicating that high SUV was associated with more significantly higher risk for recurrence than low SUV.

Conclusion: SUV measured in patients with esophageal cancer, reflecting the metabolic activity of tumor and malignancy, could serve as a prognostic factor. Considering that the FDG-PET can add important information of metabolism in detection and staging to conventional imaging modality, we anticipate that SUV could be used in patients with esophageal carcinoma.

Publication types

  • Meta-Analysis
  • Research Support, Non-U.S. Gov't
  • Review
  • Systematic Review

MeSH terms

  • Disease-Free Survival
  • Esophageal Neoplasms / diagnostic imaging*
  • Fluorodeoxyglucose F18* / pharmacokinetics
  • Humans
  • Neoplasm Staging
  • Positron-Emission Tomography / methods*
  • Prognosis
  • Radiopharmaceuticals* / pharmacokinetics

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18